Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Accumulated Expenses (2016 - 2017)

Historic Other Accumulated Expenses for Amicus Therapeutics (FOLD) over the last 6 years, with Q4 2017 value amounting to $5.4 million.

  • Amicus Therapeutics' Other Accumulated Expenses rose 13602.62% to $5.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.4 million, marking a year-over-year increase of 13602.62%. This contributed to the annual value of $5.4 million for FY2017, which is 13602.62% up from last year.
  • According to the latest figures from Q4 2017, Amicus Therapeutics' Other Accumulated Expenses is $5.4 million, which was up 13602.62% from $2.3 million recorded in Q4 2016.
  • Amicus Therapeutics' 5-year Other Accumulated Expenses high stood at $5.4 million for Q4 2017, and its period low was $275000.0 during Q4 2013.
  • In the last 4 years, Amicus Therapeutics' Other Accumulated Expenses had a median value of $679500.0 in 2014 and averaged $1.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 5109.89% in 2013, then skyrocketed by 16472.73% in 2014.
  • Quarter analysis of 4 years shows Amicus Therapeutics' Other Accumulated Expenses stood at $275000.0 in 2013, then surged by 164.73% to $728000.0 in 2014, then surged by 214.56% to $2.3 million in 2016, then soared by 136.03% to $5.4 million in 2017.
  • Its Other Accumulated Expenses stands at $5.4 million for Q4 2017, versus $2.3 million for Q4 2016 and $607000.0 for Q3 2016.